🔗 Share this article

While America proceeds with sweeping adjustments to its immunization recommendations, one figure appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by expressing skepticism about Covid shots during the pandemic and has concentrated on possible fatalities following Covid immunization in her brief position at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Public health authorities were set to announce radical changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a major change that would put the US out of alignment with a large portion of the global community with insufficient data for improved outcomes. The announcement has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to head the office this year.

A Shift at the Agency

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific pediatric immunization guidelines in the US to become more in line with the Danish model, a country with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Background

The appointee has no apparent background in pharmaceutical research, oversight or management, which has been standard for former directors of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of the center would “grasp laws and regulations and the underlying principles of drug development”, commented Janet Woodcock. “Clearly, she lacks the kind of background that former directors who headed CBER have had.”

CDER has an immense portfolio at the FDA, she emphasized.

“Many people just zeroes in on the innovative therapies, but the generic drug division authorizes numerous generic medications. There’s a biologic copycat branch, OTC medication office and so forth, and every single one need to be managed,” Dr. Woodcock noted. “The area you overlook, that is the part that I always told people is going to bite you.”

Additionally, a substantial administrative element to the position, which manages in excess of 5,000 staff members. “It’s a massive administrative position, if you perform it correctly,” she said.

Official Statement and Disputed Programs

Regarding concerns about Dr. Høeg's qualifications and whether this selection indicates greater collaboration among FDA leaders on immunizations, a press secretary responded that the “inquiries are based on flawed presumptions”.

“Her resume is consistent with the duties of her role,” the official explained, noting the period Høeg spent advising the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's controversial priority voucher program, a controversial rapid medication authorization process that reportedly troubled her preceding directors. “By what process are these drugs being chosen for this expedited pathway? Who takes the calls?” Howard said. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he remarked, “the FDA seems to be moving towards more relaxed regulations of pharmaceuticals, aside from vaccines.”

Established Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if problematic, history, Howard have noted. She released a study using unconfirmed public submissions to assess the incidence of myocarditis following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration included altering guidelines for novel immunizations and ending “optional” immunizations, she remarked after the election on a podcast. At the agency, Høeg has reportedly proposed barring teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around true believer who commences with her preconceived notions and tailors the evidence to retrofit the data in a very misleading, fraudulent manner,” Howard argued.

Taking Control and a “Push for Payback”

Høeg became part of fellow dissenters, {like|